Citius Pharmaceuticals, Inc. (CTXR)Healthcare | Biotechnology | Cranford, United States | NasdaqCM
0.48 USD
-0.02
(-3.409%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 0.47 -0.01 (-0.006%) ⇩ (Oct. 13, 2026, 6:36 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4 a.m. EDT
Citius Pharmaceuticals presents a catastrophic long-term case driven by a brutal multi-year decline where the stock has lost nearly 99.5% of its value over nine years. The business is fundamentally broken, posting massive losses, negative free cash flow, and a deteriorating balance sheet with debt significantly outweighing equity. While the current price is low, the market has already priced in the reality that this company is failing to generate sustainable value. Short-term momentum remains deeply bearish, with the stock trading well below its moving averages and showing no signs of recovery. The options market confirms this pessimism, with traders buying insurance against further drops while ignoring any potential upside. There is no dividend to provide income, and the lack of analyst coverage or institutional confidence leaves the stock vulnerable to continued neglect and decline. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.190933 |
| MSTL | 0.192213 |
| AutoARIMA | 0.196124 |
| AutoTheta | 0.241653 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.455 |
| Revenue per Share | 0.326 |
| Market Cap | 13,067,424 |
| Forward P/E | -0.33 |
| Beta | 1.00 |
| Website | https://citiuspharma.com |
As of Oct. 10, 2026, 4 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by significant open interest in out-of-the-money puts relative to virtually nonexistent call volume. The skew suggests a consensus expectation of further price weakness rather than a catalyst for a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.64532375 |
| Address1 | 11 Commerce Drive |
| Address2 | First Floor |
| All Time High | 937.5 |
| All Time Low | 0.469 |
| Ask | 0.6931 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 162,270 |
| Average Daily Volume3 Month | 532,261 |
| Average Volume | 532,261 |
| Average Volume10Days | 162,270 |
| Beta | 1.0 |
| Bid | 0.378 |
| Bid Size | 2 |
| Book Value | 2.426 |
| City | Cranford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.476 |
| Current Ratio | 0.839 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.4998 |
| Day Low | 0.46 |
| Debt To Equity | 9.455 |
| Display Name | Citius Pharmaceuticals |
| Dividend Date | 1,496,966,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,786,737,600 |
| Earnings Timestamp Start | 1,786,737,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 1.764 |
| Enterprise Value | 12,532,342 |
| Eps Current Year | -2.03 |
| Eps Forward | -1.44 |
| Eps Trailing Twelve Months | -1.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.59334 |
| Fifty Day Average Change | -0.11733997 |
| Fifty Day Average Change Percent | -0.19776177 |
| Fifty Two Week Change Percent | -64.53238 |
| Fifty Two Week High | 2.19 |
| Fifty Two Week High Change | -1.714 |
| Fifty Two Week High Change Percent | -0.7826484 |
| Fifty Two Week Low | 0.46 |
| Fifty Two Week Low Change | 0.016000003 |
| Fifty Two Week Low Change Percent | 0.034782615 |
| Fifty Two Week Range | 0.46 - 2.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,412,256,600,000 |
| Float Shares | 26,959,796 |
| Forward Eps | -1.44 |
| Forward P E | -0.33055556 |
| Free Cashflow | -36,803,784 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | -0.022700012 |
| Fullday Change Percent | -4.6063337 |
| Fullday Price | 0.476 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.77342004 |
| Gross Profits | 5,495,268 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01795 |
| Held Percent Institutions | 0.04952 |
| Implied Shares Outstanding | 27,452,570 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,732,579,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. |
| Long Name | Citius Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 13,067,424 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_272471835 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -46,274,056 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 15,669,926 |
| Number Of Analyst Opinions | 1 |
| Open | 0.481 |
| Operating Cashflow | -34,867,204 |
| Operating Margins | -6.70226 |
| Phone | 908 967 6677 |
| Post Market Change | -0.0059000254 |
| Post Market Change Percent | -1.2395011 |
| Post Market Price | 0.4701 |
| Post Market Time | 1,791,930,970 |
| Previous Close | 0.4928 |
| Price Eps Current Year | -0.23448277 |
| Price Hint | 4 |
| Price To Book | 0.19620775 |
| Price To Sales Trailing12 Months | 1.839136 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.343 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0168 |
| Regular Market Change Percent | -3.40909 |
| Regular Market Day High | 0.4998 |
| Regular Market Day Low | 0.46 |
| Regular Market Day Range | 0.46 - 0.4998 |
| Regular Market Open | 0.481 |
| Regular Market Previous Close | 0.4928 |
| Regular Market Price | 0.476 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 192,780 |
| Return On Assets | -0.26567 |
| Return On Equity | -0.81086 |
| Revenue Per Share | 0.326 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 27,452,570 |
| Shares Percent Shares Out | 0.2036 |
| Shares Short | 5,588,997 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,631,567 |
| Short Name | Citius Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.20729999 |
| Short Ratio | 28.14 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTXR |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 17,007,524 |
| Total Cash Per Share | 0.62 |
| Total Debt | 7,177,118 |
| Total Revenue | 7,105,197 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.685255 |
| Two Hundred Day Average Change | -0.20925498 |
| Two Hundred Day Average Change Percent | -0.30536804 |
| Type Disp | Equity |
| Volume | 192,780 |
| Website | https://citiuspharma.com |
| Zip | 7,016 |